First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090).

Published online

Journal Article

Background.  We report the first-in-human safety and immunogenicity evaluation of a highly attenuated, replication-competent recombinant vesicular stomatitis virus (rVSV) human immunodeficiency virus (HIV)-1 vaccine. Methods.  Sixty healthy, HIV-1-uninfected adults were enrolled in a randomized, double-blinded, placebo-controlled dose-escalation study. Groups of 12 participants received rVSV HIV-1 gag vaccine at 5 dose levels (4.6 × 10(3) to 3.4 × 10(7) particle forming units) (N = 10/group) or placebo (N = 2/group), delivered intramuscularly as bilateral injections at 0 and 2 months. Safety monitoring included VSV cultures from blood, urine, saliva, and swabs of oral lesions. Vesicular stomatitis virus-neutralizing antibodies, T-cell immunogenicity, and HIV-1 specific binding antibodies were assessed. Results.  Local and systemic reactogenicity symptoms were mild to moderate and increased with dose. No severe reactogenicity or product-related serious adverse events were reported, and all rVSV cultures were negative. All vaccine recipients became seropositive for VSV after 2 vaccinations. gag-specific T-cell responses were detected in 63% of participants by interferon-γ enzyme-linked immunospot at the highest dose post boost. Conclusions.  An attenuated replication-competent rVSV gag vaccine has an acceptable safety profile in healthy adults. This rVSV vector is a promising new vaccine platform for the development of vaccines to combat HIV-1 and other serious human diseases.

Full Text

Duke Authors

Cited Authors

  • Fuchs, JD; Frank, I; Elizaga, ML; Allen, M; Frahm, N; Kochar, N; Li, S; Edupuganti, S; Kalams, SA; Tomaras, GD; Sheets, R; Pensiero, M; Tremblay, MA; Higgins, TJ; Latham, T; Egan, MA; Clarke, DK; Eldridge, JH; HVTN 090 Study Group and the National Institutes of Allergy and Infectious Diseases HIV Vaccine Trials Network, ; Mulligan, M; Rouphael, N; Estep, S; Rybczyk, K; Dunbar, D; Buchbinder, S; Wagner, T; Isbell, R; Chinnell, V; Bae, J; Escamilla, G; Tseng, J; Fair, R; Ramirez, S; Broder, G; Briesemeister, L; Ferrara, A

Published Date

  • September 2015

Published In

Volume / Issue

  • 2 / 3

Start / End Page

  • ofv082 -

PubMed ID

  • 26199949

Pubmed Central ID

  • 26199949

International Standard Serial Number (ISSN)

  • 2328-8957

Digital Object Identifier (DOI)

  • 10.1093/ofid/ofv082


  • eng

Conference Location

  • United States